Raphael Pharmaceutical Inc. 8-K

What Happened
Raphael Pharmaceutical Inc. filed a Form 8-K (Item 5.02) reporting that Dr. Yehuda Eliya's term on the company’s Board of Directors expired and he ceased serving as a director effective December 31, 2025. The filing states Dr. Eliya’s departure was not related to any disagreement with the company regarding operations, policies, or practices.

Key Details

• Director: Dr. Yehuda Eliya.
• Effective date: December 31, 2025 (term expired and he ceased serving).
• Filing: Form 8-K under Item 5.02 (departure of directors or certain officers).
• Company disclosure: Departure not due to any disagreement with the company on operations, policies or practices.

Why It Matters
Board membership changes affect corporate governance and oversight. This filing informs investors that a director’s term concluded as scheduled and that the departure was not the result of a dispute with the company. Investors may watch for any subsequent announcements about replacements or changes to board composition, but the 8-K itself does not indicate operational or policy conflicts.